• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ACS Appl Mater Interfaces . Dual-Engineered Phage Vaccine Platform Facilitates STING Activation for Influenza Protection

tetano

Editor, Senior Moderator
ACS Appl Mater Interfaces


. 2024 Dec 26.
doi: 10.1021/acsami.4c16246. Online ahead of print. Dual-Engineered Phage Vaccine Platform Facilitates STING Activation for Influenza Protection

Fei Wang[SUP] 1 [/SUP], Shuhan Chen[SUP] 2 [/SUP], Yinhe Xia[SUP] 1 [/SUP], Caihong Liu[SUP] 3 [/SUP], Zhou Xu[SUP] 1 [/SUP], Ruilong Song[SUP] 3 [/SUP], Wenfeng Liu[SUP] 1 [/SUP], Tingting Liu[SUP] 4 [/SUP], Gang Chen[SUP] 1 [/SUP], Qingquan Liu[SUP] 2 [/SUP]



Affiliations
Abstract

Influenza epidemics remain a global public health challenge. Vaccination with nucleic acid-based vaccines, which trigger strong cellular and humoral immune responses, represents a promising approach for preventing virus infection. However, its effectiveness relies on efficient delivery and an immunoadjuvant. Here, we constructed a gene- and nanoengineered vaccine delivery platform via modifying MnO[SUB]2[/SUB] nanoparticles (NPs) onto the surface of the M13 phage, which carried the hemagglutinin stem gene of influenza A virus preceded by a eukaryotic initial transcriptional region. Specifically, the M13 phage protected the inserted nucleic acid vaccine against degradation due to the existence of capsid proteins. MnO[SUB]2[/SUB] NPs released Mn[SUP]2+[/SUP] ions under the acidic condition of endolysosomes, thereby promoting the cytoplasmic delivery of phage vaccines, which significantly improved the antigen expression. Moreover, Mn[SUP]2+[/SUP] acted as a potent adjuvant for dendritic cell maturation by activating the cGAS/STING pathway. Immunization with the engineered phage vaccine induced CD4[SUP]+[/SUP] T cell, CD8[SUP]+[/SUP] T cell, and humoral immune responses in mice. In infected mouse models, the vaccines ameliorated weight loss, survival rate, lung virus titers, and pulmonary pathologies and conferred full protection against influenza viruses. Collectively, we developed a dual-engineered phage vaccine platform, offering an alternative regimen for optimizing nucleic acid vaccines, which may have broad applications in the rational design of vaccine formulations.

Keywords: MnO2 nanoparticles; STING pathway; influenza virus; phage; vaccine delivery.

 
Back
Top Bottom